Developer docs
API playgroundTry for free, no card

Search company profiles

Olympia Pharmaceuticals

Full company profile

uuid0004yoh

Namestring
Olympia Pharmaceuticals
Legal namestring
Olympia Pharmaceuticals
Company typeenum
Private
Founded yearint
2009
Short descriptiontext

Olympia Pharmaceuticals is an FDA-registered 503B outsourcing facility and affiliated 503A compounding pharmacy in Orlando, Florida. It manufactures pharmaceutical-grade compounded medications—IV therapy, peptides, hormones, and longevity formulations—and distributes them to healthcare providers, clinics, and pharmacies nationwide, alongside sister brand Wesley Pharmaceuticals.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersOrlando, United States
HQ citystring
Orlando
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
compounding pharmacy services, 503B outsourcing facility, compounded injectable medications, IV nutritional therapy, sterile pharmaceutical manufacturing
Industry4 codes
PRIMARYHLAFALAG
Infusion & Home Infusion Pharmacy Services
Healthcare & Life Sciences/Healthcare Providers & Systems/Pharmacy & Medication Management Services
SECONDARYHLAFALAB
Hospital & Health-System Pharmacies (Inpatient/Outpatient)
Healthcare & Life Sciences/Healthcare Providers & Systems/Pharmacy & Medication Management Services
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYCRAOAHAD
Specialty Pharmacy & Biologics Distribution
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmacies and Drug Retailers456110
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Compounding Pharmacy Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1503B Compounding (Office Use)
TypeOne Time License
Description

Sale of FDA-registered 503B outsourcing facility compounded medications for office use to healthcare providers, clinics, and medical practices nationwide

olympiapharmacy.com
2503A Prescription Fulfillment
TypeSubscription Recurring
Description

Prescription-based medication fulfillment through affiliated Olympia Pharmacy, delivering compounded medications directly to patients via their healthcare providers

olympiapharmacy.com
3Consumer Wellness Products
TypeOne Time License
Description

Direct-to-consumer wellness products including OlympiaGO hydration drink mixes and OTC nutritional supplements

globenewswire.com
Marketing channels12 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Supply Chain, Operations, Infrastructure, Technology or R&D, Marketing or Sales
Pricing details1 tier
1B2B pricing for healthcare providers
ModelOtherBilling cadencePay-as-you-go
Notes

Quote-based pricing; healthcare providers and pharmacies must register accounts and contact sales team directly for pricing

olympiapharmacy.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Olympia Pharmaceuticals operates as a dual-entity pharmaceutical compounding organization: a 503B FDA-registered outsourcing facility that manufactures large-batch sterile compounded medications for office use, and an affiliated 503A state-licensed pharmacy that fulfills individual prescriptions for patients via healthcare providers. Its portfolio spans IV nutritional therapy premixes, peptide injections, hormone replacement, weight management injectables, longevity products (NAD+, Liquid Niagen), sexual health compounds, and consumer wellness hydration drink mixes (OlympiaGO).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Next-day delivery to most of Florida
+2 more records
Product overview1 text field

Olympia Pharmaceuticals operates as a dual-entity pharmacy organization consisting of a 503B FDA-registered outsourcing facility and an affiliated 503A compounding pharmacy. The company provides pharmaceutical-grade compounded medications across multiple therapeutic categories including longevity/anti-aging (NAD+ Injection, Liquid Niagen), weight management (Lipo-Mino-Mix, Lipo+, LipoStat-Plus injections, Naltrexone, Liraglutide, PeptideVite), IV nutritional therapy (Myers Cocktail, Tri-Immune Boost, Olympia Vita-Complex, Circulate), sexual health (TriMix), peptides (Sermorelin), vitamins (B12, B6, Biotin), minerals (Zinc, Magnesium, Calcium), amino acids (Glutamine, Lysine, Taurine, Arginine), and consumer wellness products (OlympiaGO hydration sticks). The 503B facility produces medications for office use with cGMP compliance, while the 503A pharmacy fulfills prescriptions directly to patients through healthcare providers. The company also partners with sister brand Wesley Pharmaceuticals for expanded distribution.

Product and service1 record
1503B Compounding Services
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-28
Description

Niagen Bioscience partnered with Olympia Pharmaceuticals as a 503B compounding partner to compound and distribute pharmaceutical-grade Niagen for its Niagen Plus intravenous and injectable products. The partnership diversifies Niagen Bioscience's 503B network beyond existing partner Wells Pharma of Houston, expanding supply chain capabilities to support growth across clinic footprint nationwide. The collaboration addresses growing demand for Niagen IV and injections in the healthy aging and longevity market.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-11
Description

Wesley Pharmaceuticals is a Florida-based 503B outsourcing facility and sister company of Olympia Pharmaceuticals. Olympia supplies products from its existing portfolio to Wesley, which distributes through its nationwide client network. Wesley launched NAD+ sourced from Olympia's portfolio, expanding access to compounded wellness products within Olympia's ecosystem. Wesley is currently licensed in 29 states with further expansion planned throughout 2026.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Existing 503B compounding network partner of Niagen Bioscience. Olympia Pharmaceuticals joined the network alongside Wells Pharma, providing additional manufacturing and distribution capacity.

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Global leader in pharmaceutical compounding with significant 503B and 503A operations in the U.S. Direct competitor to Olympia in sterile injectable and office-use compounded medications, with overlapping product categories including hormones, peptides, and IV therapy.

TypeDirect peer
Description

One of the largest FDA-registered 503B outsourcing facilities in the U.S., specializing in sterile injectable compounded medications for hospitals and clinics. Directly comparable to Olympia's 503B office-use business, particularly in the sterile injectable and IV therapy categories Olympia serves.

TypeBroad incumbent
Description

One of the largest 503B outsourcing networks in the U.S., owned by B. Braun. Overlaps with Olympia's 503B sterile compounding business but operates at significantly larger scale across hospitals and health systems.

TypeDirect peer
Description

Specialty compounding pharmacy offering both 503A patient-specific prescriptions and 503B office-use sterile products. Comparable to Olympia across the dual 503A/503B model, with overlapping therapies in hormone replacement, IV nutrition, and wellness.

5Triangle Compounding Pharmacy
TypeEmerging player
Description

Specialty compounding pharmacy with a 503B-sterile program, focused on hormone replacement, peptides, and weight management. Comparable to Olympia in therapeutic-category mix but operates at smaller scale and primarily regional footprint.

TypeDirect peer
Description

FDA-registered 503B outsourcing facility explicitly named as a 503B compounding network partner of Niagen Bioscience alongside Olympia. Direct competitor in sterile injectable compounding and the same Niagen Plus product line Olympia now produces.

TypeDirect peer
Description

503B outsourcing facility specializing in sterile admixtures and pre-filled syringes for hospital and clinic use. Comparable to Olympia's 503B business in customer base (hospitals/clinics) and regulatory profile (cGMP, FDA-registered).

TypeEmerging player
Description

Tech-enabled specialty and compounding pharmacy with prescription fulfillment directly to patients. Partially comparable to Olympia's 503A direct-to-patient prescription fulfillment channel and automated refill service, though primarily a tech/retail pharmacy rather than a 503B outsourcer.

TypeDirect peer
Description

FDA-registered 503B outsourcing facility producing ready-to-administer sterile injectable medications, with overlap to Olympia's office-use product set including ophthalmic, analgesic, and surgical compounds. Operates at a comparable cGMP-compliance tier.

10Edge Pharma
TypeDirect peer
Description

FDA-registered 503B outsourcing facility producing sterile injectable compounded medications, with a focus on ophthalmic, inhalation, and injectable products for hospitals. Comparable to Olympia in cGMP sterile injectable compounding and the office-use sales channel.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Olympia Pharmaceuticals

Compounding Pharmacy Servicesolympiapharmacy.com

Olympia Pharmaceuticals is an FDA-registered 503B outsourcing facility and affiliated 503A compounding pharmacy in Orlando, Florida. It manufactures pharmaceutical-grade compounded medications—IV therapy, peptides, hormones, and longevity formulations—and distributes them to healthcare providers, clinics, and pharmacies nationwide, alongside sister brand Wesley Pharmaceuticals.

Olympia Pharmaceuticals firmographics

Firmographics
Name
Olympia Pharmaceuticals
Legal name
Olympia Pharmaceuticals
Website
https://olympiapharmacy.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
101–250 employees
Short description
Olympia Pharmaceuticals is an FDA-registered 503B outsourcing facility and affiliated 503A compounding pharmacy in Orlando, Florida. It manufactures pharmaceutical-grade compounded medications—IV therapy, peptides, hormones, and longevity formulations—and distributes them to healthcare providers, clinics, and pharmacies nationwide, alongside sister brand Wesley Pharmaceuticals.
Ownership category
akta.pro rank

Olympia Pharmaceuticals industry classification

Industry
Product category
Compounding Pharmacy Services
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmacies and Drug Retailers (456110)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAFALAG
Infusion & Home Infusion Pharmacy Services
Healthcare & Life Sciences/Healthcare Providers & Systems/Pharmacy & Medication Management Services
SECONDARYHLAFALAB
Hospital & Health-System Pharmacies (Inpatient/Outpatient)
Healthcare & Life Sciences/Healthcare Providers & Systems/Pharmacy & Medication Management Services
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYCRAOAHAD
Specialty Pharmacy & Biologics Distribution

Keywords

  • Compounding pharmacy services
  • 503B outsourcing facility
  • Compounded injectable medications
  • IV nutritional therapy
  • Sterile pharmaceutical manufacturing

Where Olympia Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Orlando
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Olympia Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Supply Chain, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

  1. 503B Compounding (Office Use): Sale of FDA-registered 503B outsourcing facility compounded medications for office use to healthcare providers, clinics, and medical practices nationwide
  2. 503A Prescription Fulfillment: Prescription-based medication fulfillment through affiliated Olympia Pharmacy, delivering compounded medications directly to patients via their healthcare providers
  3. Consumer Wellness Products: Direct-to-consumer wellness products including OlympiaGO hydration drink mixes and OTC nutritional supplements

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goB2B pricing for healthcare providers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels12 records

Olympia Pharmaceuticals product offering

Product offering

Core offering

Olympia Pharmaceuticals operates as a dual-entity pharmaceutical compounding organization: a 503B FDA-registered outsourcing facility that manufactures large-batch sterile compounded medications for office use, and an affiliated 503A state-licensed pharmacy that fulfills individual prescriptions for patients via healthcare providers. Its portfolio spans IV nutritional therapy premixes, peptide injections, hormone replacement, weight management injectables, longevity products (NAD+, Liquid Niagen), sexual health compounds, and consumer wellness hydration drink mixes (OlympiaGO).

Product overview

Olympia Pharmaceuticals operates as a dual-entity pharmacy organization consisting of a 503B FDA-registered outsourcing facility and an affiliated 503A compounding pharmacy. The company provides pharmaceutical-grade compounded medications across multiple therapeutic categories including longevity/anti-aging (NAD+ Injection, Liquid Niagen), weight management (Lipo-Mino-Mix, Lipo+, LipoStat-Plus injections, Naltrexone, Liraglutide, PeptideVite), IV nutritional therapy (Myers Cocktail, Tri-Immune Boost, Olympia Vita-Complex, Circulate), sexual health (TriMix), peptides (Sermorelin), vitamins (B12, B6, Biotin), minerals (Zinc, Magnesium, Calcium), amino acids (Glutamine, Lysine, Taurine, Arginine), and consumer wellness products (OlympiaGO hydration sticks). The 503B facility produces medications for office use with cGMP compliance, while the 503A pharmacy fulfills prescriptions directly to patients through healthcare providers. The company also partners with sister brand Wesley Pharmaceuticals for expanded distribution.

Differentiator

Problem solved

Functional benefit

Products and services

  • 503B Compounding Services

Quantifiable outcome

  • Next-day delivery to most of Florida
  • +2 more outcomes

Companies that use Olympia Pharmaceuticals

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles4 records

Olympia Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Olympia Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Niagen BiosciencecoreStrategic or Co-development Partner · 28 April 2026Niagen Bioscience partnered with Olympia Pharmaceuticals as a 503B compounding partner to compound and distribute pharmaceutical-grade Niagen for its Niagen Plus intravenous and injectable products. The partnership diversifies Niagen Bioscience's 503B network beyond existing partner Wells Pharma of Houston, expanding supply chain capabilities to support growth across clinic footprint nationwide. The collaboration addresses growing demand for Niagen IV and injections in the healthy aging and longevity market.
  • Wesley PharmaceuticalscoreStrategic or Co-development Partner · 11 February 2026Wesley Pharmaceuticals is a Florida-based 503B outsourcing facility and sister company of Olympia Pharmaceuticals. Olympia supplies products from its existing portfolio to Wesley, which distributes through its nationwide client network. Wesley launched NAD+ sourced from Olympia's portfolio, expanding access to compounded wellness products within Olympia's ecosystem. Wesley is currently licensed in 29 states with further expansion planned throughout 2026.
  • Wells Pharma of HoustonminorChannel Partner/ Reseller/ DistributorExisting 503B compounding network partner of Niagen Bioscience. Olympia Pharmaceuticals joined the network alongside Wells Pharma, providing additional manufacturing and distribution capacity.

Scale indicators3 records

Recent moves10 records

Expansion highlights6 records

Olympia Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Fagron: Global leader in pharmaceutical compounding with significant 503B and 503A operations in the U.S. Direct competitor to Olympia in sterile injectable and office-use compounded medications, with overlapping product categories including hormones, peptides, and IV therapy.
  • QuVa Pharma: One of the largest FDA-registered 503B outsourcing facilities in the U.S., specializing in sterile injectable compounded medications for hospitals and clinics. Directly comparable to Olympia's 503B office-use business, particularly in the sterile injectable and IV therapy categories Olympia serves.
  • Anazao Health: Specialty compounding pharmacy offering both 503A patient-specific prescriptions and 503B office-use sterile products. Comparable to Olympia across the dual 503A/503B model, with overlapping therapies in hormone replacement, IV nutrition, and wellness.
  • Wells Pharma of Houston: FDA-registered 503B outsourcing facility explicitly named as a 503B compounding network partner of Niagen Bioscience alongside Olympia. Direct competitor in sterile injectable compounding and the same Niagen Plus product line Olympia now produces.
  • SCA Pharma: 503B outsourcing facility specializing in sterile admixtures and pre-filled syringes for hospital and clinic use. Comparable to Olympia's 503B business in customer base (hospitals/clinics) and regulatory profile (cGMP, FDA-registered).
  • Leiters Health: FDA-registered 503B outsourcing facility producing ready-to-administer sterile injectable medications, with overlap to Olympia's office-use product set including ophthalmic, analgesic, and surgical compounds. Operates at a comparable cGMP-compliance tier.
  • Edge Pharma: FDA-registered 503B outsourcing facility producing sterile injectable compounded medications, with a focus on ophthalmic, inhalation, and injectable products for hospitals. Comparable to Olympia in cGMP sterile injectable compounding and the office-use sales channel.

Broad incumbents

Emerging players

  • Triangle Compounding Pharmacy: Specialty compounding pharmacy with a 503B-sterile program, focused on hormone replacement, peptides, and weight management. Comparable to Olympia in therapeutic-category mix but operates at smaller scale and primarily regional footprint.
  • Alto Pharmacy: Tech-enabled specialty and compounding pharmacy with prescription fulfillment directly to patients. Partially comparable to Olympia's 503A direct-to-patient prescription fulfillment channel and automated refill service, though primarily a tech/retail pharmacy rather than a 503B outsourcer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Olympia Pharmaceuticals social profiles

Digital presence

Olympia Pharmaceuticals compliance and trust

Trust signal

Compliance4 records

Olympia Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Olympia Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles5 records

Olympia Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Olympia Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Olympia Pharmaceuticals

What does Olympia Pharmaceuticals do?

Olympia Pharmaceuticals operates as a dual-entity pharmaceutical compounding organization: a 503B FDA-registered outsourcing facility that manufactures large-batch sterile compounded medications for office use, and an affiliated 503A state-licensed pharmacy that fulfills individual prescriptions for patients via healthcare providers. Its portfolio spans IV nutritional therapy premixes, peptide injections, hormone replacement, weight management injectables, longevity products (NAD+, Liquid Niagen), sexual health compounds, and consumer wellness hydration drink mixes (OlympiaGO).

Is Olympia Pharmaceuticals a public or private company?

Olympia Pharmaceuticals is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Olympia Pharmaceuticals founded?

Olympia Pharmaceuticals was founded in 2009. It employs 101 to 250 people.

Where is Olympia Pharmaceuticals based?

Olympia Pharmaceuticals is headquartered in Orlando, United States, in the North America region.

How does Olympia Pharmaceuticals make money?

Three revenue lines are on record. 503B Compounding (Office Use) is the primary driver. The others are 503A Prescription Fulfillment and consumer Wellness Products.

Who are Olympia Pharmaceuticals's main competitors?

Direct peers on record are Fagron, QuVa Pharma, Anazao Health, Wells Pharma of Houston, SCA Pharma, Leiters Health and Edge Pharma. Central Admixture Pharmacy Services (CAPS / B. Braun) is listed as a broad incumbent. Emerging players are Triangle Compounding Pharmacy and Alto Pharmacy.

Does Olympia Pharmaceuticals have an API?

No public API is recorded for Olympia Pharmaceuticals.

What industry is Olympia Pharmaceuticals in?

Olympia Pharmaceuticals's product category is Compounding Pharmacy Services. Its primary akta.pro industry code is HLAFALAG, Infusion & Home Infusion Pharmacy Services, with a secondary code of HLAFALAB, Hospital & Health-System Pharmacies (Inpatient/Outpatient). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialOlympia Pharmaceuticals To Compound Select Peptides Under HHS Interim Enforcement PolicyOlympia Pharmaceuticals announced its 503A pharmacy will begin compounding select peptides under HHS enforcement policy, starting with BPC-157 for patients with prescriptions. The company plans to add KPV, TB-500, MOTS-c, semax, and epitalon, with availability by December. It aims to expand to 503B facilities to meet demand.BioSpaceOlympia Pharmaceuticals Introduces Polidocanol 2% Injection for Targeted Cosmetic Vein TreatmentOlympia Pharmaceuticals launched Polidocanol 2% injection for cosmetic spider and reticular vein treatment, available in 30 mL IV vials. The formulation acts as a sclerosant and local anesthetic, and is now available to order across 49 states for clinical office use.BioSpaceOlympia Pharmaceuticals Advances Longevity Offerings With Advanced Injectable CoQ10 FormulationOlympia Pharmaceuticals launched a new CoQ10 injectable in an MCT oil base, 20 mg/mL in 30 mL vials for IM or SQ use. The formulation targets mitochondrial and cardiovascular health, bypassing GI barriers for reliable uptake. It is now available to order across 49 states for clinical office use and patient-specific prescriptions.The Manila TimesOlympia Pharmaceuticals Advances Longevity Offerings With Advanced Injectable CoQ10 FormulationOlympia Pharmaceuticals announced the launch of a new 20 mg/mL injectable Coenzyme Q-10 (CoQ-10) formulation designed for mitochondrial and cardiovascular health support. The product, delivered in an MCT oil base to improve absorption and reduce discomfort, is now available for clinical use across 49 U.S. states.GlobeNewswireWesley Pharmaceuticals Expands Longevity Portfolio with Launch of Three Essential Injectable FormulationsWesley Pharmaceuticals launched three injectable formulations—Methylcobalamin, Glutathione, and Magnesium Chloride—in 30mL multi-dose vials. The products target cellular optimization, antioxidant support, and mitochondrial function, expanding the company's 503(b)-compliant lineup.Business Wire BlogNiagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™Niagen Bioscience, Inc. announced a new partnership with Olympia Pharmaceuticals, a U.S. FDA-registered 503B outsourcing facility, to compound and distribute pharmaceutical-grade Niagen for its Niagen Plus intravenous and injectable products. The addition diversifies Niagen Bioscience's 503B compounding network beyond its existing partner Wells Pharma of Houston, expanding supply chain capabilities to support growth across its clinic footprint. The company cited growing demand for Niagen IV and injections as the driver for expanding its manufacturing and distribution network nationwide.BioSpaceNiagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™Niagen Bioscience announced a partnership with Olympia Pharmaceuticals to compound and distribute pharmaceutical-grade Niagen for its Niagen Plus IV and injectable products. Olympia, a 503B facility, joins Wells Pharma to expand the company's 503B network and supply chain. The partnership aims to meet growing demand for Niagen IV and injections.POLITICOThe groups backing RFK Jr. are running low on cashA POLITICO analysis found that MAHA PAC and its linked Super PAC aligned with Health and Human Services Secretary Robert F. Kennedy Jr. have only about $412,000 in available cash, despite leaders pledging to raise $100 million to support Republicans. Over 40 percent of the $1.5 million raised by MAHA PAC since January 2025 has come from biopharma companies, including entities like Chartwell Pharmaceuticals, Olympia Pharmaceuticals, and biotech firms tied to Kennedy ally Lou Reese. The findings have drawn criticism from Democratic Senator Chris Murphy, who called the PAC a "moral and ethical mess" given Kennedy's longstanding criticism of the pharmaceutical industry he now regulates.Towards HealthcareU.S. 503B Compounding Pharmacies Market to Reach USD 1.35 Billion in 2026The U.S. 503B compounding pharmacies market was valued at USD 1.25 billion in 2025 and is projected to grow to USD 1.35 billion in 2026 and USD 2.61 billion by 2035, representing a CAGR of 7.63% during the forecast period. Sterile compounded drugs dominate the market at 68% share, while injections and infusions lead formulation types at 38%, with pain management being the largest therapeutic application segment at 24%. Key players in the market include SCA Pharma, Nephron Pharmaceuticals Corporation, Athenex, Olympia Pharmacy, and Fagron Compounding Pharmacies, with recent activity including Revelation Pharma's acquisition of Cascade Specialty Pharmacy and Olympia Pharmaceuticals' expansion into Alabama.GlobeNewswireOlympia Pharmaceuticals Unveils Circulate, Expanding Its Single-Dose IV Nutritional Therapy LineOlympia Pharmaceuticals launched Circulate, a single-dose IV premix injection for vascular health, containing Arginine, Niacinamide, Pyridoxine, and Taurine. The product aims to simplify IV protocols by reducing bag punctures and is available with a prescription or through a medical provider.